Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10

J. Feher, B. Kovacs, I. Kovács, M. Schvöller, A. Papale, C. Balacco Gabrieli

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The aim of this randomized, double-blind, placebo-controlled clinical trial was to determine the efficacy of a combination of acetyl-L-carnitine, n-3 fatty acids, and co-enzyme Q10 (Phototrop®) on the visual functions and fundus alterations in early age-related macular degeneration (AMD). One hundred and six patients with a clinical diagnosis of early AMD were randomized to the treated or control groups. The primary efficacy variable was the change in the visual field mean defect (VFMD) from baseline to 12 months of treatment, with secondary efficacy parameters: visual acuity (Snellen chart and ETDRS chart), foveal sensitivity as measured by perimetry, and fundus alterations as evaluated according to the criteria of the International Classification and Grading System for AMD. The mean change in all four parameters of visual functions showed significant improvement in the treated group by the end of the study period. In addition, in the treated group only 1 out of 48 cases (2%) while in the placebo group 9 out of 53 (17%) showed clinically significant (>2.0 dB) worsening in VFMD (p = 0.006, odds ratio: 10.93). Decrease in drusen-covered area of treated eyes was also statistically significant as compared to placebo when either the most affected eyes (p = 0.045) or the less affected eyes (p = 0.017) were considered. These findings strongly suggested that an appropriate combination of compounds which affect mitochondrial lipid metabolism, may improve and subsequently stabilize visual functions, and it may also improve fundus alterations in patients affected by early AMD.

Original languageEnglish
Pages (from-to)154-166
Number of pages13
JournalOphthalmologica
Volume219
Issue number3
DOIs
Publication statusPublished - May 2005

Fingerprint

coenzyme Q10
Acetylcarnitine
Omega-3 Fatty Acids
Macular Degeneration
Placebos
Visual Fields
Visual Field Tests
Controlled Clinical Trials
Lipid Metabolism
Visual Acuity
Odds Ratio
Control Groups

Keywords

  • Acetyl-L-carnitine n-3 fatty acids
  • Age-related macular degeneration
  • Clinical trial
  • Coenzyme Q10
  • Drusen
  • Mitochondria
  • Visual acuity
  • Visual field

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. / Feher, J.; Kovacs, B.; Kovács, I.; Schvöller, M.; Papale, A.; Balacco Gabrieli, C.

In: Ophthalmologica, Vol. 219, No. 3, 05.2005, p. 154-166.

Research output: Contribution to journalArticle

@article{e815bc0aa72e411a8d48d3334aa45faa,
title = "Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10",
abstract = "The aim of this randomized, double-blind, placebo-controlled clinical trial was to determine the efficacy of a combination of acetyl-L-carnitine, n-3 fatty acids, and co-enzyme Q10 (Phototrop{\circledR}) on the visual functions and fundus alterations in early age-related macular degeneration (AMD). One hundred and six patients with a clinical diagnosis of early AMD were randomized to the treated or control groups. The primary efficacy variable was the change in the visual field mean defect (VFMD) from baseline to 12 months of treatment, with secondary efficacy parameters: visual acuity (Snellen chart and ETDRS chart), foveal sensitivity as measured by perimetry, and fundus alterations as evaluated according to the criteria of the International Classification and Grading System for AMD. The mean change in all four parameters of visual functions showed significant improvement in the treated group by the end of the study period. In addition, in the treated group only 1 out of 48 cases (2{\%}) while in the placebo group 9 out of 53 (17{\%}) showed clinically significant (>2.0 dB) worsening in VFMD (p = 0.006, odds ratio: 10.93). Decrease in drusen-covered area of treated eyes was also statistically significant as compared to placebo when either the most affected eyes (p = 0.045) or the less affected eyes (p = 0.017) were considered. These findings strongly suggested that an appropriate combination of compounds which affect mitochondrial lipid metabolism, may improve and subsequently stabilize visual functions, and it may also improve fundus alterations in patients affected by early AMD.",
keywords = "Acetyl-L-carnitine n-3 fatty acids, Age-related macular degeneration, Clinical trial, Coenzyme Q10, Drusen, Mitochondria, Visual acuity, Visual field",
author = "J. Feher and B. Kovacs and I. Kov{\'a}cs and M. Schv{\"o}ller and A. Papale and {Balacco Gabrieli}, C.",
year = "2005",
month = "5",
doi = "10.1159/000085248",
language = "English",
volume = "219",
pages = "154--166",
journal = "Ophthalmologica",
issn = "0030-3755",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10

AU - Feher, J.

AU - Kovacs, B.

AU - Kovács, I.

AU - Schvöller, M.

AU - Papale, A.

AU - Balacco Gabrieli, C.

PY - 2005/5

Y1 - 2005/5

N2 - The aim of this randomized, double-blind, placebo-controlled clinical trial was to determine the efficacy of a combination of acetyl-L-carnitine, n-3 fatty acids, and co-enzyme Q10 (Phototrop®) on the visual functions and fundus alterations in early age-related macular degeneration (AMD). One hundred and six patients with a clinical diagnosis of early AMD were randomized to the treated or control groups. The primary efficacy variable was the change in the visual field mean defect (VFMD) from baseline to 12 months of treatment, with secondary efficacy parameters: visual acuity (Snellen chart and ETDRS chart), foveal sensitivity as measured by perimetry, and fundus alterations as evaluated according to the criteria of the International Classification and Grading System for AMD. The mean change in all four parameters of visual functions showed significant improvement in the treated group by the end of the study period. In addition, in the treated group only 1 out of 48 cases (2%) while in the placebo group 9 out of 53 (17%) showed clinically significant (>2.0 dB) worsening in VFMD (p = 0.006, odds ratio: 10.93). Decrease in drusen-covered area of treated eyes was also statistically significant as compared to placebo when either the most affected eyes (p = 0.045) or the less affected eyes (p = 0.017) were considered. These findings strongly suggested that an appropriate combination of compounds which affect mitochondrial lipid metabolism, may improve and subsequently stabilize visual functions, and it may also improve fundus alterations in patients affected by early AMD.

AB - The aim of this randomized, double-blind, placebo-controlled clinical trial was to determine the efficacy of a combination of acetyl-L-carnitine, n-3 fatty acids, and co-enzyme Q10 (Phototrop®) on the visual functions and fundus alterations in early age-related macular degeneration (AMD). One hundred and six patients with a clinical diagnosis of early AMD were randomized to the treated or control groups. The primary efficacy variable was the change in the visual field mean defect (VFMD) from baseline to 12 months of treatment, with secondary efficacy parameters: visual acuity (Snellen chart and ETDRS chart), foveal sensitivity as measured by perimetry, and fundus alterations as evaluated according to the criteria of the International Classification and Grading System for AMD. The mean change in all four parameters of visual functions showed significant improvement in the treated group by the end of the study period. In addition, in the treated group only 1 out of 48 cases (2%) while in the placebo group 9 out of 53 (17%) showed clinically significant (>2.0 dB) worsening in VFMD (p = 0.006, odds ratio: 10.93). Decrease in drusen-covered area of treated eyes was also statistically significant as compared to placebo when either the most affected eyes (p = 0.045) or the less affected eyes (p = 0.017) were considered. These findings strongly suggested that an appropriate combination of compounds which affect mitochondrial lipid metabolism, may improve and subsequently stabilize visual functions, and it may also improve fundus alterations in patients affected by early AMD.

KW - Acetyl-L-carnitine n-3 fatty acids

KW - Age-related macular degeneration

KW - Clinical trial

KW - Coenzyme Q10

KW - Drusen

KW - Mitochondria

KW - Visual acuity

KW - Visual field

UR - http://www.scopus.com/inward/record.url?scp=20544448450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20544448450&partnerID=8YFLogxK

U2 - 10.1159/000085248

DO - 10.1159/000085248

M3 - Article

C2 - 15947501

AN - SCOPUS:20544448450

VL - 219

SP - 154

EP - 166

JO - Ophthalmologica

JF - Ophthalmologica

SN - 0030-3755

IS - 3

ER -